Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
Go back to Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026| (NASDAQ: CADL) | Delayed: 8.03 -0.35 (4.18%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.38 | 52 Week High | $ | |||
| Open | $8.33 | 52 Week Low | $ | |||
| Day High | $8.33 | P/E | N/A | |||
| Day Low | $7.91 | EPS | $ | |||
| Volume | 1,184,715 | |||||



